Skip to main content

Table 1 Patient characteristics

From: MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients

  Patient Gender Age Clinical stage AC [cm] Chemotherapy CEA CA 19-9 Type of surgery Histology Grade L/V/P cT cN ypT ypN TRG Residual cancer cells Avg/Max % Local relaps Distant relaps
Responders 01 M 30 IIIA 12 Xel N N LAR A 1 0 1 1 1 0 2 1/5 0 0
02 F 62 IIIA 13 Xel N N LAR A 2 0 x 1 1 1 2 2,5/5 0 0
03 F 67 IIA 3,5 Xel N N APR A 2 0 3 0 1 0 2 7,5/15 0 0
04 M 43 IIIA 9 Xel N N uLAR A 1 0 2 1 0 0 1 0/0 0 0
05 M 40 IIIB 5 Xel E N APR A 2 0 3 1 3 1 2 1/5 0 0
06 M 73 IIA 6,5 Xel N E uLAR A 2 0 3 0 0 0 1 0/0 0 0
07 M 68 IIIC 6 Xel E E APR A 2 0 3 2 0 0 1 0/0 0 0
08 M 58 IIIB 13 Xel N N APR A 1 0 3 1 3 0 2 2,5/40 0 Y
09 M 68 IIA 4,5 5FU N N APR A 2 0 3 0 0 0 1 0/0 0 0
10 M 43 IIA 4 Xel N N uLAR MA 2 0 3 0 0 0 1 0/0 0 0
Non-responders 11 M 63 IIIB 7 Xel E N uLAR A 2 0 3 1 2 0 4 15/50 0 0
12 M 59 IIIB 9 Xel E N LAR A 2 0 3 1 3 0 4 40/60 0 0
13 M 45 IIIC 4 Xel N N APR A 2 1P 3 2 3 1 3 7,5/50 Y Y
14 F 64 IIIC 11 Xel N N LAR A 2 0 3 2 2 0 4 50/70 0 0
15 F 60 IIIA 9 Xel N N LAR A 1 0 2 1 1 0 4 70/80 0 0
16 F 69 IIIC 8 Xel N N LAR A 1 0 3 2 3 1 4 25/70 0 0
17 M 32 IIIC 10 Xel N N LAR A 2 0 2 2 3 0 4 55/75 0 0
18 M 53 IIIC 4 Xel N N APR A 3 0 3 2 2 0 3 40/60 0 0
19 M 63 IV* 7 5FU E N APR MA 2 0 3 2 3 2 4 60/80 0 Y
20 F 52 IIA 8 Xel N N LAR A 2 0 3 0 2 1 3 60/70 0 0
  1. N – Normal; E – Elevated; LAR – Low Anterior Resection; uLAR – Ultra (extended) Low Anterior Resection; APR –Abdominoperineal Resection; A – Adenocarcinoma; MA – Mucinous Adenocarcinoma; L/V/P – Lymphatic/Vascular/Perineural Invasion; 1P – Positive Perineural Invasion; TRG – Tumor Regression Score according to Mandard et al. (10); CEA – Carcinoembryonic antigen; CA 19–9 – cancer antigen 19–9; Clinical stage – according to TNM /UICC cancer staging classification, 6th Edition (ref. 5); cT/cN – clinical staging of primary tumor (T) / regional lymphatic nodes (N); ypT/ypN – histopathological staging of primary tumor and regional lymphatic nodes after neoadjuvant treatment; Residual cancer cells (Avg/Max %) – a proportion of cancer cells in all paraffin embedded tisue slices of primary tumor histologicaly examined after neoadjuvant treatment: Average (%) / Maximum (%) of cancer cells presented in examined slices; Xel – Xeloda (capecitabine); 5FU – 5-fluorouracil; M – male; F – female; AC – distance between the anocutaneous line and distal (aboral) margin of the tumor in cm; Y – yes; * in such patient a radical metastasectomy of solitary liver metastasis was first performed, followed by neoadjuvantchemoradiotherapy for locally advanced rectal cancer.